Details for Patent: 11,266,681
✉ Email this page to a colleague
Which drugs does patent 11,266,681 protect, and when does it expire?
Patent 11,266,681 protects VEKLURY and is included in one NDA.
Protection for VEKLURY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has ten patent family members in eight countries.
Summary for Patent: 11,266,681
| Title: | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
| Abstract: | The present disclosure provides a composition comprising Compound 1, or a pharmaceutically acceptable salt thereof, cyclodextrin, and, optionally, pH adjusting agents. |
| Inventor(s): | Nate Larson, Robert G. Strickley |
| Assignee: | Gilead Sciences Inc |
| Application Number: | US16/865,209 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 11,266,681 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Recent additions to Drugs Protected by US Patent 11,266,681
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 11,266,681
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | VEKLURY | remdesivir | POWDER;INTRAVENOUS | 214787-001 | Oct 22, 2020 | RX | Yes | Yes | 11,266,681*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,266,681
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 112271 | ⤷ Start Trial | |||
| Canada | 3077489 | ⤷ Start Trial | |||
| China | 111093627 | ⤷ Start Trial | |||
| China | 117982682 | ⤷ Start Trial | |||
| European Patent Office | 3651734 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
